Condition: Hodgkin Lymphoma · Hodgkin Disease · Advanced Hodgkin Lymphoma · Sponsor: National Research Center for Hematology, Russia
This is a single-center, open-label, phase 2 pilot study evaluating the efficacy and safety of a response-adapted first-line treatment strategy for patients with classical Hodgkin lymphoma (cHL) and unfavorable prognostic factors. The FINISH protocol (First-line Immuno-chemotherapy Navigated by Interim PET for Stratification and Hazard minimization In Hodgkin lymphoma) integrates nivolumab into induction therapy and tailors subsequent treatment based on interim PET-CT response. The study also includes exploratory monitoring of circulating tumor DNA (ctDNA) to investigate its role in early response assessment and residual disease detection.
This description comes directly from the study's public registry record.
Anna A Kravtsova, MD · +74956122361 · kravtsovaanna95@gmail.com
Yana K Mangasarova, MD · +74956122361 · v.k.jana@mail.ru
Always discuss trial participation with your own doctor first.
| National Medical Research Center for Hematology | Moscow, Russia | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07209059